Description
Niclosing (Niclosamide) 500 mg
Niclosing 500 mg is a niclosamide-containing medicine used as an oral anthelmintic for intestinal tapeworm infections. Niclosamide is an established antiparasitic agent with a long record of use in human medicine for cestode infestations.
Active Ingredient and Medicine Class
The verified active ingredient is niclosamide. It belongs to the anthelmintic class of antiparasitic medicines and is used against certain intestinal tapeworms (cestodes).
Established Medical Uses
Niclosamide is established for the treatment of intestinal tapeworm infections, including common human cestode infections such as Taenia species. Older reviews and clinical summaries describe it as a standard therapy for intestinal cestodes.
How It Works
Niclosamide acts locally in the intestine against tapeworms. Its best-established action is disruption of parasite energy production, including uncoupling oxidative phosphorylation, which helps stop the worm from surviving in the gut. More recent scientific reviews note that the full mechanism is not completely defined.
Important Safety Information
Important safety considerations include hypersensitivity to niclosamide or excipients, and the need for caution where tapeworm infection may involve locations beyond the intestine. Published sources also note that niclosamide is not available as a human medicine in the United States, reflecting differences in market authorisation rather than the underlying pharmacology. Clinically relevant drug-interaction details are not consistently stated in the sources reviewed here, so they are omitted.
Possible Side Effects
Reported adverse effects are mainly gastrointestinal and generally include nausea, vomiting, abdominal discomfort and diarrhoea. Reviews and product information also describe less common reactions such as dizziness, headache, rash or other hypersensitivity reactions.
Scientific Evidence
Peer-reviewed reviews consistently describe niclosamide as a long-used anthelmintic for tapeworm infections. Human data also support a generally acceptable safety profile in taeniasis control programmes, although gastrointestinal adverse events can occur. The evidence base for non-parasitic repurposed uses exists, but those uses are not established indications for this product.
Medical Information Notice
This educational summary is based on sources available at the time of review and does not replace the official patient leaflet, prescribing information or individual professional assessment.
